Can a new daily pill shrink the spleen and ease myelofibrosis symptoms?

This phase 2 trial is testing whether an oral drug called flonoltinib maleate can help adults with myelofibrosis, a rare bone marrow disorder that often causes an enlarged spleen and severe symptoms. The study compares three different daily doses (50 mg, 75 mg, and 100 mg) to see which one works best at reducing spleen size and improving symptom burden. Participants will take the drug daily and attend regular clinic visits for monitoring, including imaging scans and symptom diaries. The goal is to find a dose that offers meaningful benefit for people whose disease has not been adequately controlled by standard JAK inhibitor therapy.